NCT07056790 Research on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer
| NCT ID | NCT07056790 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | First Affiliated Hospital of Fujian Medical University |
| Condition | Prostate CA |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-05-15 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 40 participants in total. It began in 2025-05-15 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
68Ga-PSMA-CYC is a novel radiotracer targeting PSMA. In this study, we investigated the safety, biodistribution, radiation dosimetry of 68Ga-PSMA-CYC PET/CT in patients with prostate cancer, and performed a head-to-head comparison with 68Ga-PSMA-617 and 68Ga-PSMA-11 to evaluate its diagnostic performance.
Eligibility Criteria
Inclusion Criteria: * confirmed treated or untreated prostate cancer patients; * signed written consent. Exclusion Criteria: * known allergy against PSMA; * any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Contact & Investigator
Weibing Miao, MD
PRINCIPAL INVESTIGATOR
First Affiliated Hospital of Fujian Medical University
Frequently Asked Questions
Who can join the NCT07056790 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 80 Years, studying Prostate CA. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07056790 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07056790 currently recruiting?
Yes, NCT07056790 is actively recruiting participants. Contact the research team at miaoweibing@126.com for enrollment information.
Where is the NCT07056790 trial being conducted?
This trial is being conducted at Fuzhou, China.
Who is sponsoring the NCT07056790 clinical trial?
NCT07056790 is sponsored by First Affiliated Hospital of Fujian Medical University. The principal investigator is Weibing Miao, MD at First Affiliated Hospital of Fujian Medical University. The trial plans to enroll 40 participants.